Table 2. Associations of MAC clinicopathologic and molecular characteristics with cancer relapse.

Characteristic	Stage I to III			Stage III
	No. of patientsa	Relapse-free survival (%)	P Value	No. of patientsb	Relapse-free survival (%)	P-value
Gender			0.605			0.255
Female	29	75.9		17	70.6
Male	31	67.7		12	41.7
Age			0.172			0.335
≤ 70 years	33	63.6		18	50
> 70 years	27	81.5		11	72.7
Location			0.001			< 0.001
Proximal colon	33	90.9		13	100
Distal colon or rectum	27	48.1		16	25
Differentiation			0.78			0.307
Well	10	80		5	80
Moderate	43	69.8		19	47.4
Poor	7	71.4		5	80
pT status			0.225			0.043
pT1 or pT2 or pT3	51	74.5		26	65.4
pT4	9	55.6		3	0
pN status			0.091			0.578
pN0	31	83.9		-	-
pN1	20	60		20	60
pN2	9	55.6		9	55.6
AJCC TNM stage			0.035	-	-	-
Stage I or II	31	83.9
Stage III	29	58.6
SAC morphology	(n=56)		0.144	(n=27)		0.035
Absent	34	67.6		17	47.1
Present	22	86.4		10	90
CIMP status	(n=56)		0.091	(n=26)		0.009
Negative	44	63.6		18	33.3
Positive	12	91.7		8	100
SAC morphology and CIMP-positive status	(n=54)		0.035	(n=25)		0.005
Presence of both or either one	26	88.5		12	91.7
Absence of both	28	60.7		13	30.8	0.488
KRAS status	(n=55)		0.467	(n=28)
Wild type	33	72.7		16	62.5
Mutant	22	63.6		12	50
BRAF status	(n=55)		0.643	(n=28)		0.214
Wild type	46	69.6		22	50
Mutant	9	77.8		6	83.3
MMR status			0.093			0.241
Proficient	44	65.9		21	52.4
Defective	16	87.5		8	75

AJCC, American Joint Committee on Cancer; CIMP, CpG island methylator phenotype; MAC, mucinous adenocarcinoma; MMR, DNA mismatch repair; HR, hazard ratio; SAC, serrated adenocarcinoma.

^a Values are calculated for 60 patients unless specified otherwise.

^b Values are calculated for 29 patients unless specified otherwise.